Modulation of GABAA receptor binding in human brain by neuroactive steroids: Species and brain regional differences

Synapse ◽  
1995 ◽  
Vol 19 (2) ◽  
pp. 77-87 ◽  
Author(s):  
Quyen Nguyen ◽  
Douglas W. Sapp ◽  
Paul C. Van Ness ◽  
Richard W. Olsen
1989 ◽  
Vol 28 (05) ◽  
pp. 181-186
Author(s):  
A. Ludolph ◽  
O. Schober ◽  
G. Lottes ◽  
I. Böttger ◽  
H.-F. Beer ◽  
...  

99mTc-HMPAO-SPECT and SPECT with the 123I-labelled benzodiazepine (Bz) receptor ligand Ro 16-0154 were performed in 10 patients suffering from partial epilepsy, without cerebral lesion in MRT or CT. 2 h p.i. of Ro 16-0154 the distribution of activity correlated with the known distribution of Bz- receptors in the human brain. Perfusion and receptor-binding were found decreased in 7 patients of each study in the suspicious brain-area. 123l-labelled Ro 16-0154 is suitable for Bz-receptor mapping by SPECT. The decrease of Bz-receptor binding in epileptic foci, as described in PET-studies, was also detected by SPECT in 7 of 10 patients.


2010 ◽  
Vol 25 ◽  
pp. 1571
Author(s):  
C. Spindelegger ◽  
P. Stein ◽  
W. Wadsak ◽  
M. Fink ◽  
M. Mitterhauser ◽  
...  

2010 ◽  
Vol 21 (1) ◽  
pp. 1-10 ◽  
Author(s):  
Richard J. Beninger ◽  
Jonathan Beuk ◽  
Tomek J. Banasikowski ◽  
Michael van Adel ◽  
Gregory A. Boivin ◽  
...  

2005 ◽  
Vol 507 (1-3) ◽  
pp. 69-76 ◽  
Author(s):  
Taiji Yoshino ◽  
Masahiro Noguchi ◽  
Hiroko Okutsu ◽  
Aishi Kimoto ◽  
Masao Sasamata ◽  
...  

NeuroImage ◽  
2008 ◽  
Vol 41 (2) ◽  
pp. 260-269 ◽  
Author(s):  
Elina Salmi ◽  
Sargo Aalto ◽  
Jussi Hirvonen ◽  
Jaakko W. Långsjö ◽  
Anu T. Maksimow ◽  
...  

2016 ◽  
Vol 72 ◽  
pp. 1-8 ◽  
Author(s):  
David F. Werner ◽  
Patrizia Porcu ◽  
Kevin N. Boyd ◽  
Todd K. O'Buckley ◽  
Jenna M. Carter ◽  
...  

Pain ◽  
2009 ◽  
Vol 143 (1) ◽  
pp. 12-20 ◽  
Author(s):  
Hsien-Yu Peng ◽  
Gin-Den Chen ◽  
Shin-Da Lee ◽  
Cheng-Yuan Lai ◽  
Chun-Hsien Chiu ◽  
...  

2019 ◽  
Vol 22 (5) ◽  
pp. 329-338 ◽  
Author(s):  
Louisa J Steinberg ◽  
Harry Rubin-Falcone ◽  
Hanga C Galfalvy ◽  
Joshua Kaufman ◽  
Jeffrey M Miller ◽  
...  

2020 ◽  
Vol 7 ◽  
Author(s):  
Amod Kulkarni ◽  
Evelína Mochnáčová ◽  
Petra Majerova ◽  
Ján Čurlík ◽  
Katarína Bhide ◽  
...  

Neisseria adhesin A (NadA), one of the surface adhesins of Neisseria meningitides (NM), interacts with several cell types including human brain microvascular endothelial cells (hBMECs) and play important role in the pathogenesis. Receptor binding pockets of NadA are localized on the globular head domain (A33 to K69) and the first coiled-coil domain (L121 to K158). Here, the phage display was used to develop a variable heavy chain domain (VHH) that can block receptor binding sites of recombinant NadA (rec-NadA). A phage library displaying VHH was panned against synthetic peptides (NadA-gdA33−K69 or NadA-ccL121−K158), gene encoding VHH was amplified from bound phages and re-cloned in the expression vector, and the soluble VHHs containing disulfide bonds were overexpressed in the SHuffle E. coli. From the repertoire of 96 clones, two VHHs (VHHF3–binding NadA-gdA33−K69 and VHHG9–binding NadA-ccL121−K158) were finally selected as they abrogated the interaction between rec-NadA and the cell receptor. Preincubation of NM with VHHF3 and VHHG9 significantly reduced the adhesion of NM on hBMECs in situ and hindered the traversal of NM across the in-vitro BBB model. The work presents a phage display pipeline with a single-round of panning to select receptor blocking VHHs. It also demonstrates the production of soluble and functional VHHs, which blocked the interaction between NadA and its receptor, decreased adhesion of NM on hBMECs, and reduced translocation of NM across BBB in-vitro. The selected NadA blocking VHHs could be promising molecules for therapeutic translation.


Sign in / Sign up

Export Citation Format

Share Document